利拉鲁肽应用于2型糖尿病合并非酒精性脂肪肝患者的疗效

Efficacy of laluropeptide in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

目的:探讨利拉鲁肽应用于2型糖尿病合并非酒精性脂肪肝患者的疗效。方法:将2017年6月-2018年6月在我院内分泌科治疗的96例2型糖尿病合并非酒精性脂肪肝患者随机分为两组,对照组单用二甲双胍治疗,在此基础上观察组使用利拉鲁肽,比较两组患者的血脂及肝肾功能指标变化、糖代谢及炎性因子水平变化。结果:观察组治疗后TG、AST、γ-GT、SUA、UAER明显低于对照组,ADP明显升高(P<0.05);观察组治疗后FBG、2 hPG、HbA1c、FGF21、hs-CRP、MDA明显低于对照组,而SOD明显高于对照组(P<0.05)。结论:利拉鲁肽应用于2型糖尿病合并非酒精性脂肪肝患者的疗效显著,能有效改善血糖、血脂代谢紊乱,抑制肝脏脂肪沉积,改善氧化应激和组织慢性炎症,具有积极的临床意义。

Objective:To explore the efficacy of laluropeptide in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.Methods:96 patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease treated in endocrinology department of our hospital from June 2017 to June 2018 were randomly divided into two groups.The control group was treated with metformin alone,and on this basis,the observation group was treated with laluropeptide,and the changes in blood lipid,liver and kidney function indexes,glucose metabolism and inflammatory factor levels of the two groups were compared.Results:After treatment,TG,AST,γ-GT,SUA and UAER in the observation group were significantly lower than those in the control group,and ADP was significantly increased(P<0.05).After treatment,FBG,2 hPG,HbA1c,FGF21,hs-CRP and MDA in the observation group were significantly lower than those in the control group,while SOD was significantly higher than that of the control group(P<0.05).Conclusion:The application of laluropeptide in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease had significant curative effect.It could effectively relieve the disorder of blood glucose and lipid metabolism,inhibit hepatic fat deposition,improve oxidative stress and chronic inflammation of tissues,and had positive clinical significance.